1 active not recruiting, 1 completed. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Non-Cutaneous Melanoma: new trials by email Literature Review of Non-Cutaneous Melanoma trials Research Report on Non-Cutaneous Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma TBio-4101, Cyclophosphamide, Fludarabine - Metastatic Melanoma, Unresectable Melanoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2022-11-22 | 2026-04-02 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
Melanoma (2) · Uveal Melanoma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2) · Eye Diseases (1) · Eye Neoplasms (1) · Uveal Diseases (1) · Uveal Neoplasms (1)
CTLA-4 Antigen (1) · Cyclophosphamide (1) · Interferon alpha-2 (1) · Interleukin-2 (1) · Introns (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · fludarabine (1) · fludarabine phosphate (1) · pembrolizumab (1)
H. Lee Moffitt Cancer Center and Research Institute (1) · National Cancer Institute (NCI) (1)
United States (2) · Canada (1) · Ireland (1)
Amod Sarnaik, MD (1) · Sapna Patel (1)
U10CA180888 (1)